GET DAILY SIGNALSIllumina (ILMN) Delivers Q3 Beat but Shares Drop 12% After Hours
Key Takeaways
- Illumina reported third-quarter fiscal 2026 revenue of $1.13 billion, up 4.2% from $1.08 billion a year earlier, though slightly below the roughly $1.15 billion consensus on a reported basis.
- Adjusted (non-GAAP) diluted earnings per share (EPS) rose 7% to $1.44, topping the $1.36 analysts expected.
- Revenue excluding one-time tariff refunds was $1.17 billion, above the $1.15 billion estimate.
- Non-GAAP operating margin improved to 25.0%, and free cash flow climbed to $378 million from $253 million a year earlier.
- Management raised full-year 2026 guidance to revenue of $4.64 billion–$4.66 billion and adjusted EPS of $5.40–$5.45.
- Despite the beat, shares slid roughly 12% in after-hours trading as investors focused on China and softer research-market demand.
Why This Quarter Matters
Illumina is the leading maker of DNA sequencing systems used by research institutions, clinical labs, pharmaceutical companies, and genomics providers. This quarterly report matters because it serves as a key read on the company's transition to its flagship NovaSeq X platform, the balance between resilient clinical demand and a still-soft research market, and management's push beyond hardware into software, artificial intelligence (AI), and data. Coming into the report, the stock had surged roughly 120% year to date, raising the bar for what investors needed to hear. The results confirmed strengthening margins and cash flow, but a sharp after-hours selloff signaled that the market was looking for clearer evidence of accelerating growth. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
For the third quarter of fiscal 2026, ended September 27, 2026, Illumina reported revenue of $1.13 billion, up 4.2% from $1.08 billion in the prior-year period. On a non-GAAP basis excluding tariff refunds, revenue was $1.17 billion, topping the roughly $1.15 billion consensus estimate.
GAAP diluted EPS was $1.43, up from $0.98 a year earlier, while adjusted (non-GAAP) diluted EPS reached $1.44, a 7% increase from $1.34 and above the $1.36 consensus. Net income climbed to $220 million from $150 million a year ago.
Profitability improved across the board. Non-GAAP gross margin expanded 20 basis points to 69.4%, and non-GAAP operating margin rose to 25.0%. Free cash flow reached $378 million, up from $253 million in the prior-year quarter.
By segment, sequencing consumables revenue grew 6% to $792 million, driven by 14% growth in clinical markets, while research-and-applied consumables declined 6%. Sequencing instruments revenue fell 2% organically to $106 million, and sequencing service and other revenue rose 8% to $158 million.
Management raised its full-year 2026 outlook to revenue of $4.64 billion–$4.66 billion and adjusted EPS of $5.40–$5.45, and guided fourth-quarter revenue to $1.22 billion–$1.24 billion. From what I see, the underlying operational strength here stands out even with the one-time items.
Market Reaction and Investor Sentiment
Illumina's headline beat failed to satisfy investors. Shares closed the regular session at $290.06, up 0.44%, before falling roughly 12% in after-hours trading to around $255.88. The decline came despite EPS and revenue (excluding tariff refunds) beating consensus and an upward revision to full-year guidance.
The selloff reflected several concerns rather than the headline numbers themselves. China revenue declined 0.1% during the quarter, research-and-applied consumables continued to contract, and sequencing instruments revenue slipped on an organic basis. With the stock near its 52-week high ahead of the report, elevated expectations left little room for anything short of a stronger growth signal. Investors also appeared to want more clarity on the 2027 outlook, which management said it would provide with fourth-quarter results.
Forward Outlook and Key Factors to Monitor
Looking ahead, Illumina's trajectory will hinge on a few key themes. First is the NovaSeq X transition. Management said roughly 84% of high-throughput volume and 60% of revenue now sit on the X platform, with research-and-applied conversion largely complete. The remaining clinical conversion is expected to reach 80%–85% in coming quarters, which should reduce year-over-year pricing headwinds into 2027.
Second, investors should watch the divergence between clinical and research demand. Clinical consumables grew 14%, while research-and-applied consumables declined 6%. A sustained recovery in research spending would provide a meaningful catalyst, and management noted early signs that research activity is stabilizing. I’m watching this closely as the clinical side continues to show resilience.
Third, the company's newer software and data initiatives — including the Billion Cell Atlas and BioInsight platform — are increasingly central to its strategy. These efforts are still early and not yet a major financial contributor, but management expects them to become more visible in 2027 and beyond.
Finally, China and tariff-related dynamics remain watch items. Tariff refunds provided a one-time benefit to margins and EPS in the quarter that is not expected to repeat, making the underlying operating performance the more relevant measure for future quarters.
Using AI Tools in My Research Process
In my own analysis of earnings reports like this one, I frequently rely on Tickeron’s AI Screener to quickly filter for comparable names in the life sciences space and spot any emerging technical patterns that might influence how the market digests the results. It helps surface context without replacing the core fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for ILMN shows an upward move is likely
ILMN's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 214 similar instances where the Aroon Indicator showed a similar pattern. In 178 of the 214 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ILMN as a result. In 72 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for ILMN just turned positive on October 29, 2026. Looking at past instances where ILMN's MACD turned positive, the stock continued to rise in 34 of 56 cases over the following month. The odds of a continued upward trend are 61%.
Following a +3.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where ILMN advanced for three days, in 204 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The 10-day RSI Indicator for ILMN moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 15 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 58%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ILMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
ILMN broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 1 (best 1 - 100 worst), indicating outstanding price growth. ILMN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.433) is normal, around the industry mean (66.893). P/E Ratio (53.814) is within average values for comparable stocks, (2.527). Projected Growth (PEG Ratio) (3.355) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (7.843) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ILMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of integrated systems for the analysis of genetic variation and function
Industry MedicalSpecialties
Advertisement